Wigal, Tim L.
Newcorn, Jeffrey H. http://orcid.org/0000-0001-8993-9337
Handal, Nelson
Wigal, Sharon B.
Mulligan, Ioulietta
Schmith, Virginia http://orcid.org/0000-0003-2841-2384
Konofal, Eric http://orcid.org/0000-0002-7284-0987
Funding for this research was provided by:
NLS-1 Pharma AG
Article History
First Online: 19 March 2018
Compliance with Ethical Standards
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of Schulman Institutional Review Board and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study prior to any study procedures.
: This study was sponsored by NLS-1 Pharma AG. The open access fee was paid by NLS-1 Pharma AG.
: The study was sponsored by NLS-1 Pharma AG. All coauthors are paid consultants of NLS-1 Pharma AG. EK is the inventor of the patent for the use of mazindol in ADHD and VS is the inventor of the patent for mazindol CR. Other COIs including as Consultant, Advisory Board, Research Support: Akili Interactive (TW JN SW), Alcobra (JN), Arbor (JN), Cingulate (JN SW), Enzymotec (JN), Ironshore (TW SW JN), KenPharm (JN), Lundbeck (JN), Medic (JN), Neos (JN), Neurovance (TW SW), NFL (JN), Pfizer (SW) Purdue (TW SW), Rho (SW), Rhodes (TW SW JN), Shire (TW SW JN), Sunovion (TW SW JN), Supernus (JN), Tris Pharma (TW SW).